Myelopathy associated with acute leukemia. Multidisciplinary view on the problem

Leukemia-associated myelitis is a rare but underestimated complication. It has a different etiology associated with both, the main disease and its treatment methods. It requires differential diagnosis with funicular myelosis, polyradiculoneuropathy, tumor and hemorrhagic formation, stroke, dysmetabolic manifestations, as well as with the consequences of treatment of the underlying disease using radiation, cytostatic, targeted therapy.It should also be differentiated from paraneoplastic myelopathy and progression of the underlying disease. However,with the help of neuroimaging methods, it can be detected more recently than a detailed clinical picture appears. A case report of myelopathy in a 31 year old patient with acute lymphoblastic leukemia is presented. Treatment of the underlying disease was carried out with the use of chemotherapy, radiation therapy, allogeneic hematopoietic stem cell transplantation and targeted therapy. The nature of the disease,i.e. recurrent course of acute lymphoblastic leukemia, the variety of treatment methods, and the absence of focal changes in neuroimaging in the zone that determines clinical manifestations, made it necessary to consider a wide range of possible etiological factors for the development of myelopathy. Myelopathy was confirmed by MRI 2.5 months after the debut of neurological symptoms, which corresponds to modern concepts and time criteria for visualization in neurooncology. The article presents the criteria for diagnosing myelopathy, a complication of acute lymphoblastic leukemia. It should also be differentiated from However, with the help of neuroimaging methods, it can be detected more recently than a detailed clinical picture appears.

1. Alakel N., Stölzel F., Mohr B., Kramer M., Oelschlägel U., Röllig C., Bornhäuser M., Ehninger G., Schaich M. Symptomatic central nervous system involvement in adult patients with acute myeloid leukemia. Cancer Manag. Res. 2017;9:97–102. https://doi.org/10.2147/CMAR.S125259

2. Frishman-Levy L., Izraeli S. Advances in understanding the pathogenesis of CNS acute lymphoblastic leukaemia and potential for therapy. British Journal of Haematology. 2017;176(2):157–167. https://doi.org/10.1111/bjh.14411

3. Joseph P., Reyes M. Dorsal Column Myelopathy Following Intrathecal Chemotherapy for Acute Lymphoblastic Leukemia. J. Spinal Cord. Med. 2014;37(1):107–13. https://doi.org/10.1179/2045772312Y.0000000081

4. Beh S.C., Greenberg B.M., Frohman T., Frohman E.M. Transverse myelitis. Neurol. Clin. 2013;31(1):79–138. https://doi.org/10.1016/j.ncl.2012.09.008

5. Xing L., Wen S., Niu Z., Wang F., Zhang X. Rituximab for acute demyelinating myelopathy after allogeneic hematopoietic stem cell transplantation: a case report. Postgrad. Med. 2020;9:1–4. https://doi.org/10.1080/00325481.2020.1736884

6. Parovichnikova E.N., Klyasova G.A., Troitskaya V.V. Sokolov A.N., Kuzmina L.A., Mendeleeva L.P. et al. Efficiency of treatment of adult patients with acute T-lymphoblastic leukemia according to the ALL-2009 protocol of the Russian Acute Leukemia Study Group. Ter. Arch. 2013;85(8):29–34]. URL: https://ter-arkhiv.ru/0040-3660/article/view/31297

7. Kim H.J., Ryu K.N., Choi W.S., Choi B.K., Choi J.M., Yoon Y. Spinal involvement of hematopoietic malignancies and metastasis: differentiation using MR imaging. Clin. Imaging. 1999;23(2):125–33. https://doi.org/10.1016/s0899-7071(99)00105-9

8. Nguyen T., Palacio A., Beuret-Blanquart F. Paraplegia after intrathecal injection of Methotrexate. Annals of Physical and Rehabilitation Medicine. 2011;54(1):e162–e167. https://doi.org/10.1016/j.rehab.2011.07.513

9. Pan Y., Wang C., Wang H., Tao Q., Xiong S., Zhai Z. Transverse myelopathy occurring with intrathecal administration of methotrexate and cytarabine chemotherapy: A case report. Oncology Letters. 2016;11:4066–4068. https://doi.org/10.3892/ol.2016.4519

10. Lee H.Y., Sung-il I., Myoung-Hee Kang, Im S-il, Kang M.-H., Kim K.M. et al. Irreversible Paraplegia Following One Time Prophylactic Intrathecal Chemotherapy in an Adult Patient With Acute Lymphoblastic Leukemia. Yonsei Med. J. 2008;49(1):151–4. https://doi.org/10.3349/ymj.2008.49.1.151

11. Froklage F.E., Reijneveld J.C., Heimans J.J. Central neurotoxicity in cancer chemotherapy: pharmacogenetic insights. Pharmacogenomics. 2011;12(3):379–95. https://doi.org/10.2217/pgs.10.197

12. Dornbos D. 3rd, Elder J., Otero J., Baiocchi R.A., Slone H.W., Puduvalli V.K. et al. Spinal Cord Toxicity From Intrathecal Chemotherapy: A Case With Clinicopathologic Correlation. World Neurosurg. 2019;128:381–384. https://doi.org/10.1016/j.wneu.2019.05.123

13. EMA/289046/2017 Committee for Medicinal Products for Human Use (CHMP). URL: https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-usechmp-18-21-april-2017

14. Kelm S., Pelz A., Schauer R., Filbint M.T., Tang S., de Bellard M.-E. et al. Sialoadhesin, Myelin-Associated Glycoprotein and CD22 Define a New Family of Sialic Acid-Dependent Adhesion Molecules of the Immunoglobulin Superfamily. Curr. Biol. 1994;4(11):965–72. https://doi.org/10.1016/s0960-9822(00)00220-7

15. Kantarjian H., Thomas D., Jorgensen J., Kebriaei P., Jabbour E., Rytting M. et al. Results of Inotuzumab Ozogamicin, a CD22 Monoclonal Antibody in Refractory and Relapsed Acute Lymphocytic Leukemia. Cancer. 2013;119(15):2728–2736. https://doi.org/10.1002/cncr.28136

16. Vincent A. Developments in autoimmune channelopathies. Autoimmun Rev. 2013;12(6):678–681. https://doi.org/10.1016/j.autrev.2012.10.016

17. Rajan T.V. The Gell-Coombs Classification of Hypersensitivity Reactions: A Re-Interpretation. Trends Immunol. 2003;24(7):376–9. https://doi.org/10.1016/s1471-4906(03)00142-x

18. Giometto B., Grisold W., Vitaliani R., Graus F., Honnorat J., Bertolini G., PNS Euronetwork. Paraneoplastic neurologic syndrome in the PNS Euronetwork database: A European study from 20 centers. Arch. Neurol. 2010;67:330–335. https://doi.org/10.1001/archneurol.2009.341

19. Liu Z., Jiao L., Qiu Z., Da Y Tanga Y., Lina Y., Lia D. et al. Clinical Characteristics of Patients With Paraneoplastic Myelopathy. J. Neuroimmunol. 2019;330:136–142. https://doi.org/10.1016/j.jneuroim.2019.03.001

20. Chamberlain M.C., Sandy A.D., Press G.A. Neurology. Leptomeningeal metastasis: a comparison of gadolinium-enhanced MR and contrast-enhanced CT of the brain. Press GA Neurology. 1990;40(3 Pt 1):435–8. https://doi.org/10.1212/wnl.40.3_part_1.435

21. Del Principe M.I., Maurillo L., Buccisano F., Sconocchia G., Cefalo M., De Santis G. et al. Central Nervous System Involvement in Adult Acute Lymphoblastic Leukemia: Diagnostic Tools, Prophylaxis, and Therapy. Mediterr. J. Hematol. Infect. Dis. 2014;6(1):e2014075. https://doi.org/10.4084/MJHID.2014.075.eCollection 2014

22. Thomas X., Le Q. Central nervous system involvement in adult acute lymphoblastic leukemia. Hematology. 2008;13(5):293–302. https://doi.org/10.1179/102453308X343374

23. Skullerud K., Halvorsen K. Encephalomyelopathy following intrathecal methotrexate treatment in a child with acute leukemia. Cancer. 1978;42:1211–1215. https://doi.org/10.1002/1097-0142(197809)42:3 < 1211::aid-cncr2820420326 > 3.0.co;2-x

24. Cachia D., Kamiya-Matsuoka С., Pinnix C.C., Chi L., Kantarjian H.M., Cortes J.E. et al. Myelopathy following intrathecal chemotherapy in adults: a single institution experience. J. Neurooncol. 2015;122(2):391–398. https://doi.org/10.1007/s11060-015-1727-z

25. Yong Lee H., Im S., Kang M-H., Kim K.M., Kim S.H., Kim H.-G. et al. Irreversible Paraplegia Following One Time Prophylactic Intrathecal Chemotherapy in an Adult Patient with Acute Lymphoblastic Leukemia. Yonsei Med. J. 2008;49(1):151–4. https://doi.org/10.3349/ymj.2008.49.1.151

26. Schultheiss T.E. The radiation dose–response of the human spinal cord. Int. J. Radiat. Oncol. Biol. Phys. 2008;71:1455–1459. https://doi.org/10.1016/j.ijrobp.2007.11.075

27. Wong C.S., Fehlings M.G., Sahgal A. Pathobiology of radiation myelopathy and strategies to mitigate injury. Spinal Cord. 2015;53(8):574–80. https://doi.org/10.1038/sc.2015.43

28. Wong C.S., Van Dyk J., Milosevic M., Laperriere N.J. Radiation myelopathy following single courses of radiotherapy and retreatment. Int. J. Radiat. Oncol. Biol. Phys. 1994;30(3):575–81. https://doi.org/10.1016/0360-3016(92)90943-c

29. Krasnov V.S., Bedenko A.S., Totolyan N.A., Skoromets A.A. Longitudinally extensive transverse myelitis associated with intrathecal synthesis of oligoclonal immunoglobulin G and with vitamin B12 deficiency. Nevrologiya, neiropsikhiatriya, psikhosomatika. Neurology, neuropsychiatry, psychosomatics. 2016;8(3):71–75. (In Russian) http://dx.doi.org/10.14412/2074-2711-2016-3-71-75

30. Flanagan E.P., McKeon A., Lennon V.A., Kearns J., Weinshenker B.G., Krecke K.N. et al. Paraneoplastic isolated myelopathy: clinical course and neuroimaging clues. Neurology. 2011b. 76, 2089–2095. https://doi.org/10.1212/WNL.0b013e31821f468f

31. Hemmer B., Glocker F.X., Schumacher M. Deuschl G., Lücking C.H. Subacute combined degeneration: clinical, electrophysiological, and magnetic resonance imaging findings. J. Neurol. Neurosurg. Psychiatry. 1998;65:822–827. https://doi.org/10.1136/jnnp.65.6.822

32. Kumar N., Ahlskog J.E., Klein C.J., Port J.D., Imaging features of copper deficiency myelopathy: a study of 25 cases. Neuroradiology. 2006;48(2):78–83. https://doi.org/10.1007/s00234-005-0016-5